RU-58642
RU-58642
RU-58642 (pronounced: R-U-Five-Eight-Six-Four-Two) is a synthetic compound that is often used in biomedical research. It is a nonsteroidal antiandrogen (NSAA) that was first developed in the 1980s by the French pharmaceutical company Roussel Uclaf, hence the 'RU' in its name. The numbers '58642' are simply a unique identifier for the compound.
Etymology
The name RU-58642 is derived from the initials of the company that developed it, Roussel Uclaf, and a unique identifier number '58642'. The compound is also known by its chemical name, which is 17β-hydroxy-17α-1-methyl-3-oxo-1-propenyl-4,9-estradien-3-one.
Usage
RU-58642 is primarily used in biomedical research as a nonsteroidal antiandrogen (NSAA). It is known for its high affinity to the androgen receptor (AR), where it acts as a potent antagonist. This makes it a valuable tool in the study of androgen-dependent diseases and conditions, such as prostate cancer and androgenetic alopecia (male pattern baldness).
Related Terms
- Nonsteroidal antiandrogen (NSAA): A type of medication that prevents androgens like testosterone from expressing their effects within the body.
- Androgen receptor (AR): A type of nuclear receptor that is activated by binding any of the androgenic hormones, usually testosterone or dihydrotestosterone.
- Prostate cancer: A form of cancer that develops in the prostate, a gland in the male reproductive system.
- Androgenetic alopecia: A common form of hair loss in both men and women, also known as male pattern baldness in men.
See Also
External links
- Medical encyclopedia article on RU-58642
- Wikipedia's article - RU-58642
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski